September 12, 2016 (Shareholders Foundation) - An investigation on behalf of current long-term investors in shares of Neos Therapeutics Inc (NASDAQ:NEOS) was announced over potential breaches of fiduciary duties by certain officers and directors at Neos Therapeutics.

The investigation by a law firm concerns whether certain Neos Therapeutics directors breached their fiduciary duties and caused damage to the company and its shareholders.

On October 19, 2015 Neos Therapeutics Inc announced that, on October 16, 2015, the Company received a notification from the U.S. Food and Drug Administration (FDA) stating that, as part of its ongoing review of the Companys New Drug Application (NDA) for Cotempla XR-ODT (Methylphenidate Extended Release Orally Disintegrating) 10 mg, 20mg, and 30 mg tablets, it has identified deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time.

Shares of Neos Therapeutics Inc (NASDAQ:NEOS) declined to as low as $11.53 per share on October 22, 2015.

On August 11, 2016, Neos Therapeutics Inc reported its second quarter 2016 financial results.

Shares of Neos Therapeutics Inc (NASDAQ:NEOS) declined to as low as $6.81 per share on August 11, 2016.